These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35847924)

  • 1. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience.
    Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NS; Chua DTT; Lee SWM; Chen JS; Yeh CN
    Front Oncol; 2022; 12():883399. PubMed ID: 35847924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
    Zalcberg JR
    Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
    Symcox M; Jones RL
    Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.
    Li J; Cai S; Zhou Y; Zhang J; Zhou Y; Cao H; Wu X; Deng Y; Huang Z; Dong J; Shen L
    Clin Cancer Res; 2022 Aug; 28(16):3425-3432. PubMed ID: 35686969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study.
    Yang W; Qian H; Yang L; Wang P; Qian H; Chu B; Liu Z; Sun J; Wu D; Sun L; Zhou W; Hu J; Chen X; Shou C; Ruan L; Zhang Y; Yu J
    Front Oncol; 2023; 13():1180795. PubMed ID: 37274264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors.
    Thirasastr P; Somaiah N
    Clin Exp Gastroenterol; 2023; 16():11-19. PubMed ID: 36798653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fourth-line rescue treatment ripretinib of advanced small intestine gastrointestinal stromal tumors who achieved partial response: a case report.
    Liu B; Kou Y
    J Gastrointest Oncol; 2022 Jun; 13(3):1505-1513. PubMed ID: 35837161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.
    Wu C; Zhang J; Wu X
    Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
    George S; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Razak AA; Gordon MS; Somaiah N; Jennings J; Meade J; Shi K; Su Y; Ruiz-Soto R; Janku F
    Eur J Cancer; 2021 Sep; 155():236-244. PubMed ID: 34391056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
    Zalcberg JR; Heinrich MC; George S; Bauer S; Schöffski P; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Somaiah N; Meade J; Reichert V; Shi K; Sherman ML; Ruiz-Soto R; von Mehren M; Blay JY
    Oncologist; 2021 Nov; 26(11):e2053-e2060. PubMed ID: 34313371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
    Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
    Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.
    Li J; Zhang J; Zhang Y; Qiu H; Zhou Y; Zhou Y; Zhang X; Zhou Y; Zhu Y; Li Y; Wang M; Shen K; Tao K; Wu X; Wang H; Zhang B; Ling J; Ye Y; Wu X; Qu H; Ma Y; Jiao X; Zheng H; Jin J; Liu Z; Tan M; Fang Y; Zhang P; Zhang N; Lei C; Cai Z; Liang B; Peng Z; Huang Z; Dong J; Shen L
    Eur J Cancer; 2024 Jan; 196():113439. PubMed ID: 37980854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience.
    Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NSM; Chua DTT; Lee SWM; Chen JS; Yeh CN
    Front Oncol; 2022; 12():1028118. PubMed ID: 36313668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review.
    Zhang Y; Huang Z
    Front Pharmacol; 2023; 14():1122885. PubMed ID: 37288114
    [No Abstract]   [Full Text] [Related]  

  • 15. Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.
    Zhang X; Zhang P; Qiu H; Fang Y; Liu H; Zhou Y; Xu H; Yu J; Zhang J; Wang M; Shen L; Li J
    Adv Ther; 2023 Sep; 40(9):3817-3829. PubMed ID: 37356078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.
    Schöffski P; George S; Heinrich MC; Zalcberg JR; Bauer S; Gelderblom H; Serrano C; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Becker C; Shi K; Meade J; Ruiz-Soto R; Blay JY; von Mehren M
    BMC Cancer; 2022 Dec; 22(1):1302. PubMed ID: 36514034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study.
    Lim SY; Ferro-López L; Barquin E; Lindsay D; Thway K; Smith MJ; Benson C; Jones RL; Napolitano A
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward.
    Lostes-Bardaji MJ; García-Illescas D; Valverde C; Serrano C
    Ther Adv Med Oncol; 2021; 13():1758835920986498. PubMed ID: 33473249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.
    Symcox M; Somaiah N
    Future Oncol; 2021 Dec; 17(36):5007-5012. PubMed ID: 34661454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
    Kurokawa Y; Honma Y; Sawaki A; Naito Y; Iwagami S; Komatsu Y; Takahashi T; Nishida T; Doi T
    Ann Oncol; 2022 Sep; 33(9):959-967. PubMed ID: 35688358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.